For citations:
Tereshchenko S.N., Glezer M.G., Abugov S.A., Averkov O.V., Antipov S.I., Galyavich A.S., Gilyarov M.Yu., Duplyakov D.V., Efremushkina A.A., Zateyshchikov D.A., Ivanenko V.V., Kosmacheva E.D., Krestyaninov O.V., Lopatin Yu.M., Panchenko E.P., Ryabov V.V., Samokhvalov E.V., Staroverov I.I., Ustyugov S.A., Khripun A.V., Shalaev S.V., Shakhnovich R.M., Yavelov I.S., Yakovlev A.N., Yakushin S.S. Place of Prasugrel, P2Y12 receptor antagonist, in an early invasive treatment of patients with acute coronary syndrome (according to the results of multicenter randomized controlled trial ISAR-REACT 5). Russian Journal of Cardiology. 2019;(11):92-97. (In Russ.) https://doi.org/10.15829/1560-4071-2019-11-92-97
Email this article 